HLB Life Science Co., Ltd. (KOSDAQ: 067630)
South Korea flag South Korea · Delayed Price · Currency is KRW
9,750.00
+40.00 (0.41%)
Dec 27, 2024, 9:00 AM KST

HLB Life Science Statistics

Total Valuation

HLB Life Science has a market cap or net worth of KRW 1.22 trillion. The enterprise value is 1.27 trillion.

Market Cap 1.22T
Enterprise Value 1.27T

Important Dates

The next estimated earnings date is Wednesday, March 19, 2025.

Earnings Date Mar 19, 2025
Ex-Dividend Date n/a

Share Statistics

HLB Life Science has 121.81 million shares outstanding. The number of shares has increased by 0.22% in one year.

Current Share Class n/a
Shares Outstanding 121.81M
Shares Change (YoY) +0.22%
Shares Change (QoQ) +8.42%
Owned by Insiders (%) n/a
Owned by Institutions (%) 6.75%
Float 97.91M

Valuation Ratios

The trailing PE ratio is 14.93.

PE Ratio 14.93
Forward PE n/a
PS Ratio 10.92
PB Ratio 2.75
P/TBV Ratio 3.21
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings 17.92
EV / Sales 13.11
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF -21.70

Financial Position

The company has a current ratio of 1.36, with a Debt / Equity ratio of 0.38.

Current Ratio 1.36
Quick Ratio 1.28
Debt / Equity 0.38
Debt / EBITDA n/a
Debt / FCF -2.80
Interest Coverage -1.31

Financial Efficiency

Return on equity (ROE) is 21.64% and return on invested capital (ROIC) is -3.48%.

Return on Equity (ROE) 21.64%
Return on Assets (ROA) -3.36%
Return on Capital (ROIC) -3.48%
Revenue Per Employee 669.72M
Profits Per Employee 489.98M
Employee Count 145
Asset Turnover 0.19
Inventory Turnover 14.55

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -14.77% in the last 52 weeks.

Beta (5Y) n/a
52-Week Price Change -14.77%
50-Day Moving Average 9,507.80
200-Day Moving Average 11,798.65
Relative Strength Index (RSI) 58.47
Average Volume (20 Days) 414,066

Short Selling Information

Short Interest n/a
Short Previous Month n/a
Short % of Shares Out n/a
Short % of Float n/a
Short Ratio (days to cover) n/a

Income Statement

In the last 12 months, HLB Life Science had revenue of KRW 97.11 billion and earned 71.05 billion in profits. Earnings per share was 671.75.

Revenue 97.11B
Gross Profit -3.20B
Operating Income -27.60B
Pretax Income 74.38B
Net Income 71.05B
EBITDA -21.34B
EBIT -27.60B
Earnings Per Share (EPS) 671.75
Full Income Statement

Balance Sheet

The company has 113.62 billion in cash and 164.62 billion in debt, giving a net cash position of -51.00 billion or -418.70 per share.

Cash & Cash Equivalents 113.62B
Total Debt 164.62B
Net Cash -51.00B
Net Cash Per Share -418.70
Equity (Book Value) 433.60B
Book Value Per Share 3,650.80
Working Capital 36.33B
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -30.36 billion and capital expenditures -28.33 billion, giving a free cash flow of -58.69 billion.

Operating Cash Flow -30.36B
Capital Expenditures -28.33B
Free Cash Flow -58.69B
FCF Per Share -481.81
Full Cash Flow Statement

Margins

Gross margin is -3.29%, with operating and profit margins of -28.42% and 73.16%.

Gross Margin -3.29%
Operating Margin -28.42%
Pretax Margin 76.60%
Profit Margin 73.16%
EBITDA Margin -21.98%
EBIT Margin -28.42%
FCF Margin n/a

Dividends & Yields

HLB Life Science does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -0.22%
Shareholder Yield -0.22%
Earnings Yield 6.70%
FCF Yield -4.80%

Stock Splits

The last stock split was on December 28, 2022. It was a forward split with a ratio of 1.0516983.

Last Split Date Dec 28, 2022
Split Type Forward
Split Ratio 1.0516983

Scores

HLB Life Science has an Altman Z-Score of 4.63.

Altman Z-Score 4.63
Piotroski F-Score n/a